Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

por Gennari, A, Bruzzi, P, Orlandini, C, Salvadori, B, Donati, S, Landucci, E, Guarneri, V, Rondini, M, Ricci, S, Conte, P
Publicado 2004

Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features.

por Ménard, S., Squicciarini, P., Luini, A., Sacchini, V., Rovini, D., Tagliabue, E., Veronesi, P., Salvadori, B., Veronesi, U., Colnaghi, M. I.
Publicado 1994

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

por Baldini, E, Prochilo, T, Salvadori, B, Bolognesi, A, Aldrighetti, D, Venturini, M, Rosso, R, Carnino, F, Gallo, L, Giannessi, P, Conte, P F, Orlandini, C, Bruzzi, P
Publicado 2004

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

por Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F
Publicado 2004